May 11, 2022
Launched Recorlev® and Gvoke® Kit Achieved Q1 net product revenue of $21.9M – a 33% increase from same period prior year on a pro forma basis Ended Q1 with $132.1M in cash, cash equivalents and short-term investments Affirming 2022 guidance for combined net product revenues of $105M - $120M , $50M
Jan 18, 2022
  Preliminary 2021 full-year pro forma net sales at high-end of $76-80 million guidance, representing approximately 55% growth from 2020 Year-end 2021 preliminary cash, cash equivalents, and investments of approximately $102 million 20+ million Medicaid lives in IL, TN, PA, OH, and CA have